KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Liabilities from Discontinued Operations: 2022

  • Travere Therapeutics' Liabilities from Discontinued Operations was N/A to $64.2 million in Q4 2022 from the same period last year, while for Dec 2022 it was $64.2 million, marking a year-over-year change of. This contributed to the annual value of $64.2 million for FY2022, which is N/A change from last year.
  • Travere Therapeutics' Liabilities from Discontinued Operations amounted to $64.2 million in Q4 2022.
  • In the past 5 years, Travere Therapeutics' Liabilities from Discontinued Operations registered a high of $64.2 million during Q4 2022, and its lowest value of $64.2 million during Q4 2022.
  • Moreover, its 1-year median value for Liabilities from Discontinued Operations was $64.2 million (2022), whereas its average is $64.2 million.